Status:
UNKNOWN
Impact of Sedation With HFNOT on tcPCO2, mitoPO2 and mitoVO2.
Lead Sponsor:
Calvin de Wijs, MSc
Conditions:
Sedation Complication
High Flow Nasal Oxygen Therapy
Eligibility:
All Genders
18+ years
Brief Summary
Deep procedural sedation has seen an increased use indication over the last couple of years aided by the introduction of high flow nasal oxygen therapy (HFNOT) during these procedures. However, this l...
Eligibility Criteria
Inclusion
- Age over 18 years
- Acceptable proficiency of the Dutch language
- Scheduled for a procedure requiring deep procedural sedation with HFNOT.
Exclusion
- Porphyria
- Known intolerance to components of the ALA plaster
- Presence of mitochondrial disease
- Pregnancy/lactation
- Patients with skin lesions on the measurement location which impede measurements
- Incapability to provide inform consent, due to a mental condition interfering with the ability to understand the provided information
Key Trial Info
Start Date :
February 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06124027
Start Date
February 13 2023
End Date
November 30 2023
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015GD